Last reviewed · How we verify

NCT05759819

Evaluate the Efficacy and Safety of the Cilostazol-coated BioMimics 3D Stent System in Patients with Peripheral Arterial Occlusive Disease

Active, enrolled NA Last updated 7 February 2025
What this trial tests

NA trial testing Standard stenting in Peripheral Arterial Disease in 24 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
10 March 2023
Primary endpoint
5 December 2024
31 December 2026

Quick facts

Lead sponsorOtsuka Medical Devices Co., Ltd. Japan
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment24
Start date10 March 2023
Primary completion5 December 2024
Estimated completion31 December 2026
Sites5 locations across Japan

Drugs / interventions tested

Conditions studied

Sponsor

Otsuka Medical Devices Co., Ltd. Japan — full company profile →

Who can join

18 and older, any sex, with Peripheral Arterial Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An exploratory evaluation of the efficacy and safety of CLZ-BM3D for the treatment of symptomatic peripheral occlusive arterial disease of the superficial femoral artery or proximal popliteal artery

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Peripheral Arterial Disease

Currently open trials in the same condition.

Other Otsuka Medical Devices Co., Ltd. Japan trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05759819.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing